Regeneron Pharmaceuticals Inc
NASDAQ:REGN

Watchlist Manager
Regeneron Pharmaceuticals Inc Logo
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Watchlist
Price: 718.36 USD -0.61% Market Closed
Market Cap: 75.5B USD

Regeneron Pharmaceuticals Inc
Cash Equivalents

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Regeneron Pharmaceuticals Inc
Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Cash Equivalents
$2.5B
CAGR 3-Years
-10%
CAGR 5-Years
10%
CAGR 10-Years
14%
Abbvie Inc
NYSE:ABBV
Cash Equivalents
$5.6B
CAGR 3-Years
-22%
CAGR 5-Years
-7%
CAGR 10-Years
-5%
Gilead Sciences Inc
NASDAQ:GILD
Cash Equivalents
$9.4B
CAGR 3-Years
26%
CAGR 5-Years
-6%
CAGR 10-Years
-4%
Amgen Inc
NASDAQ:AMGN
Cash Equivalents
$9.4B
CAGR 3-Years
0%
CAGR 5-Years
1%
CAGR 10-Years
11%
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Cash Equivalents
$1.5B
CAGR 3-Years
12%
CAGR 5-Years
25%
CAGR 10-Years
26%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Cash Equivalents
$6.3B
CAGR 3-Years
-12%
CAGR 5-Years
3%
CAGR 10-Years
24%
No Stocks Found

Regeneron Pharmaceuticals Inc
Glance View

In the vibrant world of biotechnology, Regeneron Pharmaceuticals Inc. emerged as a powerhouse by meticulously weaving together science and medicine. Founded in 1988 by a visionary team, including celebrated scientists Dr. Leonard Schleifer and Dr. George Yancopoulos, Regeneron was created with an ambitious mission to harness the power of biology to bring innovative medicines to patients. The company began its journey with a strong emphasis on research and development, evolving its unique approach to drug discovery focused on the rapid and precise identification of biologically relevant targets. With a strategic location at the heart of New York's biotechnology valley, Regeneron thrived, investing substantially in proprietary technologies and developing a robust pipeline of therapeutics aimed at addressing critical unmet medical needs across various domains such as ophthalmology, immunology, oncology, and rare diseases. Today, Regeneron makes its mark in the pharmaceutical industry primarily through its innovative product portfolio, comprised of renowned drugs like EYLEA, a leading treatment for retinal diseases, and Dupixent, a medication for atopic dermatitis and other allergic conditions. The company's revenue model relies heavily on the commercial success of these drugs, supported by strategic collaborations and partnerships with industry giants like Sanofi. Their success is driven by a commitment to leveraging cutting-edge technology platforms, such as the VelociSuite, which expedites drug discovery and development processes. Regeneron’s emphasis on precision and quality, coupled with an agile business model that adapts to health landscapes, allows it to maintain a competitive edge in a rapidly evolving industry while consistently delivering robust financial performance.

REGN Intrinsic Value
728.57 USD
Undervaluation 1%
Intrinsic Value
Price

See Also

What is Regeneron Pharmaceuticals Inc's Cash Equivalents?
Cash Equivalents
2.5B USD

Based on the financial report for Sep 30, 2025, Regeneron Pharmaceuticals Inc's Cash Equivalents amounts to 2.5B USD.

What is Regeneron Pharmaceuticals Inc's Cash Equivalents growth rate?
Cash Equivalents CAGR 10Y
14%

Over the last year, the Cash Equivalents growth was 25%. The average annual Cash Equivalents growth rates for Regeneron Pharmaceuticals Inc have been -10% over the past three years , 10% over the past five years , and 14% over the past ten years .

Back to Top